<DOC>
	<DOCNO>NCT02143830</DOCNO>
	<brief_summary>The purpose study determine whether use low dos busulfan elimination cyclosporine reduce transplant-related side effect patient Fanconi Anemia ( FA ) . Patients undergo transplant utilize mis-matched relate match unrelated donor follow preparative regimen busulfan , fludarabine , anti-thymocyte globulin cyclophosphamide .</brief_summary>
	<brief_title>HSCT Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy</brief_title>
	<detailed_description>The trial propose three arm phase II treatment protocol design investigate safety efficacy risk-adjusted chemotherapy-based cytoreductive regimen plus CD34+ select T-cell deplete peripheral blood stem cell ( PBSC ) stem cell transplant treatment patient Fanconi anemia severe hematologic disease . Candidates trial include patient Fanconi anemia present severe marrow failure ( transfusion dependent ) myelodysplastic syndrome , acute myelogenous leukemia allogeneic stem cell transplant indicate .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must diagnosis Fanconi anemia Patients must one follow hematologic diagnosis : 1 . Severe Aplastic Anemia ( SAA ) , bone marrow cellularity &lt; 25 % OR Severe Isolated Single Lineage Cytopenia least one follow feature : 1 . Platelet count &lt; 20 x 109/L platelet transfusion dependence* 2 . ANC &lt; 1000 x 109/L 3 . Hgb &lt; 8 gm/dl red cell transfusion dependence* 2 . Myelodysplastic Syndrome ( MDS ) ( base WHO IPSS Classification 3 . Acute Myelogenous Leukemia ( untreated , remission refractory relapse disease ) Donors either human leukocyte antigen ( HLA ) compatible unrelated HLAgenotypically match related donor ( fully match sibling donor ) . Patients donor may either gender ethnic background . Patients must Karnofsky adult , Lansky pediatric performance scale status &gt; 70 % . Patients must adequate physical function measure : 1 . Cardiac : asymptomatic symptomatic 1 ) leave ventricular ejection fraction ( LVEF ) rest must &gt; 50 % must improve exercise 2 ) Shortening Fraction &gt; 29 % 2 . Hepatic : &lt; 5 x upper limit normal ( ULN ) alanine transaminase ( ALT ) &lt; 2.0 mg/dl total serum bilirubin . 3 . Renal : serum creatinine &lt; 1.5 mg/dl serum creatinine outside normal range , CrCl &gt; 50 ml/min/1.73 m2 4 . Pulmonary : asymptomatic symptomatic , DLCO &gt; 50 % predict Each patient must willing participate research subject must sign informed consent form . Female patient donor must pregnant breastfeeding time sign consent . Women must willing undergo pregnancy test prior transplant avoid become pregnant study . Active CNS leukemia Female patient pregnant ( positive serum urine HCG ) breastfeeding . Active uncontrolled viral , bacterial fungal infection Patient seropositive HIVI/II ; HTLV I/II</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>marrow aplasia</keyword>
	<keyword>cytopenia</keyword>
	<keyword>myelodysplasia</keyword>
	<keyword>AML</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>cytoreductive regimen</keyword>
	<keyword>T-cell reduction</keyword>
</DOC>